Long term outcome of a patient with relapsed refractory early thymic precursor acute lymphoblastic leukemia treated with daratumumab.
暂无分享,去创建一个
P. Subramanian | P. Tembhare | A. Bonda | S. Punatar | Anant Gokarn | B. Bagal | N. Khattry | L. Nayak | S. Mirgh | A. Chichra
[1] Omar Castaneda Puglianini,et al. Early precursor T-cell acute lymphoblastic leukemia: current paradigms and evolving concepts , 2020, Therapeutic advances in hematology.
[2] Neha Singh,et al. Will Daratumumab be the next game changer in early thymic precursor‐acute lymphoblastic leukaemia? , 2019, British journal of haematology.
[3] G. Gahrton,et al. Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma , 2019, PloS one.
[4] J. Rowe,et al. Daratumumab in Combination with Vincristine or Nelarabine As Effective Salvage Therapy for Patients with Acute Lymphoblastic Leukemia at High Risk of Relapse , 2018, Blood.
[5] J. Connors,et al. Daratumumab for Delayed Red-Cell Engraftment after Allogeneic Transplantation. , 2018, The New England journal of medicine.
[6] J. Byrd,et al. Anti-leukemic effects of all-trans retinoic acid in combination with Daratumumab in acute myeloid leukemia , 2018, International immunology.
[7] J. Rowe,et al. Daratumumab for relapsed/refractory Philadelphia-positive acute lymphoblastic leukemia , 2018, Haematologica.
[8] A. Bonda,et al. Daratumumab at the frontiers of post-transplant refractory T-acute lymphoblastic leukemia—a worthwhile strategy? , 2018, Bone Marrow Transplantation.
[9] A. Krishnan,et al. Graft-versus-host disease (GVHD) risk with daratumumab (Dara) therapy post allogeneic transplantation (alloHCT) for multiple myeloma (MM). , 2018 .
[10] M. Loh,et al. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. , 2018, Blood.
[11] P. Moreau,et al. Daratumumab for the treatment of multiple myeloma , 2017, Expert opinion on biological therapy.
[12] R. Goldsby,et al. Daratumumab Is Effective in the Treatment of Refractory Post-Transplant Autoimmune Hemolytic Anemia: A Pediatric Case Report , 2016 .
[13] Bie M. P. Verbist,et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. , 2016, Blood.
[14] R. Groen,et al. Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab , 2015, Leukemia.
[15] G. Danet-Desnoyers,et al. Anti-Leukemic Activity of Daratumumab in Acute Myeloid Leukemia Cells and Patient-Derived Xenografts , 2014 .
[16] E. Thiel,et al. Clinical and molecular characterization of early T-cell precursor leukemia: a high-risk subgroup in adult T-ALL with a high frequency of FLT3 mutations , 2012, Blood Cancer Journal.
[17] S. Hunger,et al. Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected]. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.